Uterine sarcomas—Recent progress and future challenges
Authors:
- Beatrice M. SeddonBSBeatrice M. Seddon
- Reena DavdaRDReena Davda
- 1 April 2011
- journal article
- review article
- Published by Elsevier in European Journal of Radiology
- Vol. 78 (1) , 30-40
Abstract
No abstract availableKeywords
This publication has 150 references indexed in Scilit:
- Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II studyGynecologic Oncology, 2009
- Genetic aberrations in soft tissue leiomyosarcomaCancer Letters, 2009
- Endometrial stromal sarcoma: a population-based analysisBritish Journal of Cancer, 2008
- Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trialGynecologic Oncology, 2008
- Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II studyGynecologic Oncology, 2008
- Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcomaBritish Journal of Cancer, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysisInternational Journal of Cancer, 2006
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) StudyGynecologic Oncology, 2004